Loading…
Based on limited metadata, the FDA issued a warning letter to Jiangsu Hengrui Pharmaceuticals Co., Ltd., a pharmaceutical manufacturer, on July 11, 2024. While the specific violations are not detailed in the available metadata, the letter addresses compliance issues related to drug products. Without access to the full warning letter text, the precise nature of the manufacturing, quality control, or regulatory deficiencies cannot be determined, though such letters typically address GMP violations, quality assurance failures, or other manufacturing practice concerns.